SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

The United States Oil Fund (USO) is trending as escalating geopolitical tensions in the Middle East, driven by reports of US-Israeli strikes on Iran and subsequent retaliations, fuel widespread community discussion about potential oil supply disruptions, particularly regarding the Strait of Hormuz. Community sentiment is sharply divided between those anticipating a significant price surge and others expecting a rapid "sell the news" reversal.

SSgA Active Trust - State Street Energy Select Sector SPDR ETF

Energy Select Sector SPDR Fund

XLE is trending amidst escalating US-Iran conflict, with strikes on Gulf infrastructure and threats to the Strait of Hormuz fueling widespread fears of global oil supply disruptions and significant crude price surges. The community is actively discussing a flight to energy assets, positioning the sector for strong momentum even as broader markets anticipate risk-off sentiment.

Vanguard Group, Inc. - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amidst heightened market uncertainty driven by Federal Reserve policy, geopolitical developments, and ongoing debates about the sustainability of valuations in the tech sector. Despite some community calls for a significant correction, many investors continue to favor VOO for its broad market exposure and long-term stability.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is a focal point of intense market and social media discussion following significant military action against Iran, including the reported death of its Supreme Leader, as investors and community members weigh the geopolitical implications and ongoing controversies.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

The defense community is buzzing about Kratos Defense & Security Solutions, navigating a recent substantial stock offering against a wave of new contracts for its leading drone and hypersonic systems. Investors are keenly focused on the company's pivotal role in evolving global defense priorities and the anticipated surge in military spending.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

The $CC symbol is trending amid excitement for Canton's recent exchange listings and its Real World Asset (RWA) potential, although a significant portion of the community discussion is currently driven by "Community Coin," a charity project gaining attention for its recent donations and philanthropic model.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

INDO is trending amidst escalating Middle East tensions, with community chatter focused on US/Israel strikes in Iran and potential disruptions to the critical Strait of Hormuz, fueling expectations of a massive oil price surge and a short squeeze for this low-float energy play.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is trending after solidifying its merger with Coterra Energy, a deal poised to create a new U.S. oil and gas giant with expanded production and a focus on significant shareholder returns through increased dividends and buybacks. Investors are also monitoring ongoing geopolitical tensions, which are sparking broader interest in the energy sector.

Codatta

XNY (Codatta) is drawing significant attention for its strong performance and resilience, often showing green metrics even when the broader crypto market faces pullbacks. The community is actively discussing its potential for further breakouts and new highs, driven by its utility in powering AI and decentralized science data projects, alongside recent exchange listings.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad (MON) is trending due to recent ecosystem integrations, including Kalshi deposits and Orbs perpetuals, coupled with a notable CNBC mention and significant institutional backing. The community is actively discussing its high-performance Layer-1 technology, attractive 12% staking yield, and perceived long-term potential as it shows resilience in a volatile crypto market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments PR Newswire VANCOUVER, BC, Feb. 27...

New Strong Sell Stocks for Jan. 13

ATAI, BHR and BZH have been added to the Zacks Rank #5 (Strong Sell) List on Jan.13, 2026.

<ul class="summary-bullets"><li>GH Research is scheduled to update on the FDA status of GH001 and outline its global Phase 3 plans for treatment-resistant depression on Monday.</li><li>The update follows the company’s submission of a complete response to the FDA after a prior clinical hold.</li><li>Progress across competing psychedelic-based depression programs has increased focus on the stock.</li></ul>Shares of GH Research PLC drew increased retail attention on Monday ahead of a scheduled update on its FDA Investigational New Drug application for GH001, the company’s inhaled therapy for treatment-resistant depression, and its plans for a global Phase 3 program, due at 7:00 a.m. EST.<h2 class="st-heading-2">Phase 3 Program And FDA Update In Focus</h2>The update follows the company’s June disclosure that it submitted a complete response to the FDA addressing a previously announced clinical hold on the IND. At the time, GH Research said the submission included completed toxicology studies and comprehensive responses to the agency’s requests, adding that it had worked closely with regulators and submitted the response ahead of schedule.<h2 class="st-heading-2">GH001 Data Anchors Development Path</h2>GH001 is GH Research’s lead experimental therapy, delivered through a proprietary inhalation system and designed to treat patients with treatment-resistant depression, a condition where standard antidepressants have failed.In February 2025, the company reported results from a Phase 2b study involving 81 patients. Those treated with GH001 showed a significant improvement in depression symptoms within eight days, with scores on a standard clinical scale falling by an average of 15.5 points more than placebo. The difference was statistically significant.Over half of the patients receiving GH001 achieved remission by Day 8, compared with none in the placebo group. The company said all secondary study goals were met, and the treatment was well tolerated, with no serious adverse events reported during the blinded phase of the trial.Longer-term follow-up data showed sustained benefits. Among patients who completed six months of follow-up, nearly 78% remained in remission, with most requiring only a small number of additional treatments. As of late January 2025, the company reported no serious safety issues during this extended period.<h2 class="st-heading-2">Psychedelic Race Intensifies</h2>In November, H.C. Wainwright lowered its price target on GH Research to $35 from $40 while maintaining a ‘Buy’ rating, citing competitive momentum from programs such as Atai Beckley’s BPL-003 and AbbVie’s GM-2505, as well as the prior FDA hold.In October, Needham initiated coverage with a ‘Buy’ rating and a $19 price target, citing GH001’s Phase 2 efficacy and remission data and estimating potential U.S. sales of $1.9 billion by 2035.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for GH Research was ‘extremely bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:968/143;" src="https://news.stocktwits-cdn.com/ghrs_ss_png_215c6b80c9.webp" alt="ghrs ss.png" width="968" height="143"><figcaption>GHRS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user grouped GH Research alongside names like Disney, Marathon Digital, Critical Metals and Navitas Semiconductor, saying the stock continues to sit within a cluster of “hot themes” across the market.<stembedurl>https://stocktwits.com/JoyceFernandez/message/640797658</stembedurl>Another user said they plan to sell part of their position around the FDA update to lock in gains and hold the rest into the next company update later in the quarter.<stembedurl>https://stocktwits.com/NoobFriendly/message/640797043</stembedurl><a href="https://stocktwits.com/symbol/GHRS">GH Research’s stock</a> has risen 89% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the GH Research logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

GH Research Stock Grabs Retail Spotlight Ahead Of FDA Update On Depression Treatment

GH001 showed symptom improvement, high remission rates, and sustained benefits in a Phase 2b trial for treatment-resistant depression.

Equity

<ul class="summary-bullets"><li>The analyst noted that sponsors must continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health.</li><li>Jefferies added that it believes Atai Beckley's (ATAI) proprietary psychedelics have promise.</li><li>The AdvisorShares Psychedelics ETF (PSIL), which invests in the emerging psychedelic drugs sector, traded 1.3% higher at the time of writing.</li></ul>Jefferies analyst Andrew Tsai now sees positive tailwinds forming for non-recreational psychedelics after President Trump signed an executive order on Thursday directing his administration to reclassify marijuana.The firm now sees non-recreational psychedelics eventually follow suit, as long as sponsors continue producing study data to suggest psychedelics can safely produce profound efficacy in mental health. This, the analyst believes, is arguably a function of time.&nbsp;Jefferies added that it believes pharmaceutical company Atai Beckley's (<a href="https://stocktwits.com/symbol/ATAI">ATAI</a>) proprietary psychedelics have promise. AtaiBeckley’s pipeline includes investigational therapies for treatment-resistant depression and social anxiety disorder.Shares of psychedelics-related stocks rallied on Friday. While ATAI stock traded 0.4% higher at the time of writing, Supernus (<a href="https://stocktwits.com/symbol/SUPN">SUPN</a>) and Cybin (<a href="https://stocktwits.com/symbol/CYBN">CYBN</a>) shares rose about 5%.The AdvisorShares Psychedelics ETF (<a href="https://stocktwits.com/symbol/PSIL">PSIL</a>), which invests in the emerging psychedelic drugs sector, also traded 1.3% higher.<h2 class="st-heading-2">Trump Cannabis Order</h2>President Donald Trump on Thursday <a href="https://stocktwits.com/news-articles/markets/equity/tilray-canopy-growth-stock-rise-as-trump-signs-executive-order-to-lower-marijuana-restrictions/cLegUFuREr0">signed</a> an executive order to reschedule marijuana to make it less restrictive and available for “legitimate medical uses.” Trump is seeking to move marijuana from a schedule 1 drug to a schedule 3 drug, from the levels of heroin, down to the levels of tylenol.Trump clarified that the order is not federal legalization and does not allow for recreational use nationwide but is instead aimed at improving medical marijuana and cannabidiol research. The Centers for Medicare &amp; Medicaid Services (CMS) is also working on a plan to test making some Medicare patients eligible for therapies derived from cannabinoids or compounds derived from the Cannabis plant.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PSIL fell from ‘neutral’ to ‘bearish’ territory over the past 24 hours, while sentiment around ATAI also took a dip to ‘extremely bearish’ levels.Sentiment around SUPN stayed ‘neutral,’ while sentiment around CYBN stayed ‘extremely bullish’.A Stocktwits user highlighted a positive study from 2022 on Psilocybin, a naturally occurring psychedelic compound, in treating depression symptoms.<stembedurl>https://www.stocktwits.com/DJS777/message/639663641</stembedurl>As per the study published in the New England Journal of Medicine, participants reported a greater reduction in levels of depression three weeks after taking a 25 mg dose of psilocybin, compared to those who took the lowest 1 mg dose.PSIL has gained 68% this year and by 76% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/cassava-sciences-stock-on-track-for-worst-day-in-about-9-months/cLe0RFtREsu">Cassava Sciences Stock On Track For Worst Day In About 9 Months — What’s Driving Today’s Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Digitally generated image of brain filled with multicolored particles. | Source: Getty Images

Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order

Jefferies sees restrictions around non-recreational psychedelics eventually loosen up.  

Enhanced Fortifies Executive Leadership Team & Board of Directors

Enhanced Fortifies Executive Leadership Team & Board of Directors Enhanced Fortifies Executive Leadership Team & Board of Directors PR Newswire NEW YORK, Nov. 19, 2025 Co-Founder Maximilian Martin...

atai Life Sciences (ATAI) Upgraded to Buy: Here's Why

atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know

atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging  Halozyme Therapeutics (HALO) This Year?

Here is how Halozyme Therapeutics (HALO) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.

Here's Why atai Life Sciences (ATAI) Is a Great 'Buy the Bottom' Stock Now

atai Life Sciences (ATAI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why

atai Life Sciences (ATAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.10	--	--	N/A
Q3 '25	-$0.12	-$0.28	-142.59%	MISSED
Q2 '25	-$0.12	-$0.14	-20.00%	MISSED
Q1 '25	-$0.17	-$0.15	12.07%	BEAT
Q4 '24	-$0.14	-$0.24	-68.00%	MISSED

ATAI
ATAI Life Sciences N.V.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ATAI News

ATAIATAI Life Sciences N.V.